drugset
drugset / Trial / NCT04216758

Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer

NCT04216758 ↗

Phase 2 Unknown 300 enrolled Fudan University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Treatment, Prospective, Assignment, Open Label, Single-center, Non-randomized Study An exploratory clinical trial of comparison of Nab-Paclitaxel combined with Gemcitabine and Gemcitabine combined with Tegafur for adjuvant chemotherapy after radical resection of pancreatic cancer

Timeline

Start
2020-01-01
Primary completion
2020-07-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Nab-paclitaxel Small molecule 100 mg/m2 Intravenous
Subject Tegafur Unknown 60 mg Oral
Subject Tegafur Unknown 80 mg Oral
Subject Tegafur Unknown 100 mg Oral

Indications

pancreatic adenocarcinoma